Publications

Categories
Clinical, ZW191
October 23, 2025
AACR-EORTC-NCI
Preliminary Results From a Phase 1 First-in-Human Multicenter Open-Label Study of ZW191, a Folate Receptor α–Targeting Antibody-Drug Conjugate, in Participants With Advanced Solid Tumors
LoRusso et al.
Preclinical, ZW1528
September 30, 2025
ERS
ZW1528, a Bispecific Antibody Targeting IL-4Rα and IL-33, Potently Inhibits Key Mediators of Airway Inflammation
Hardman et al.
Preclinical, ZW1528
September 10, 2025 - September 10, 2025
World Bispecific Summit
ZW1528: A Dual-Targeting Bispecific Antibody to Broadly Suppress Airway Inflammation by Inhibiting IL-4Ra and IL-33 Pathways
Alexey Berezhnoy, PhD
Preclinical
August 11, 2025
Immuno-Oncology Summit
Engineering TrispecificT Cell Engager Leveraging Conditional CD28 Co-Stimulation to Treat Solid Tumors
Genevieve Desjardins, PhD
Preclinical
June 26, 2025
T cell Engager Summit
ZW209: A DLL3 Targeted Trispecific T Cell Engager with Conditional and Obligate cis CD28 Co-stimulation to Improve Responses in DLL3-Expressing Tumors
Nina Weisser, PhD
Clinical, ZW191
June 19, 2025
ESMO Gynaecological Cancers Congress
Design of a First-in-Human Multicentre Open-Label Study of ZW191, a Folate Receptor α–Targeting Antibody-Drug Conjugate Utilising a Novel TOPOIi Payload, in Participants With Advanced Solid Tumours: ZWI-ZW191-101
Sommerhalder et al.
Clinical, ZW171
June 2, 2025
ASCO
Design of a First-in-Human Multicenter Open-Label Study of ZW171, a Mesothelin x CD3–Targeting Bispecific T Cell Engager, in Participants With Advanced Solid Tumors: ZWI-ZW171-101
Johnson et al.
Preclinical, ZW1528
May 19, 2025
ATS
ZW1528, a Bispecific Antibody Targeting IL-4Rα and IL-33, Potently Inhibits Key Mediators of Airway Inflammation
Poffenberger et al.
Preclinical
April 30, 2025
AACR
ZW209, a DLL3 targeted trispecific T cell engager with integrated CD28 co-stimulation, demonstrates safety and potent preclinical efficacy in models of small cell lung cancer
Lau et al.
Preclinical
April 29, 2025
AACR
In vitro assays for prediction of ADC hematological toxicity: contribution of antibody, linker, and payload
Colombo et al.
ZW171
April 28, 2025
AACR
ZW171, a differentiated 2+1 T cell-engaging bispecific antibody with antitumor activity in a range of mesothelin-expressing cancers
Afacan et al.
Preclinical
April 28, 2025
AACR
ZW327, a novel Ly6E-targeting antibody-drug conjugate bearing a topoisomerase 1 inhibitor payload
Urosev et al.